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Abstract
Background: CC-family chemokine receptor 2 (CCR2) is implicated in the trafficking of blood-
borne monocytes to sites of inflammation and is implicated in the pathogenesis of several
inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and atherosclerosis. The
major challenge in the development of small molecule chemokine receptor antagonists is the lack
of cross-species activity to the receptor in the preclinical species. Rabbit models have been widely
used to study the role of various inflammatory molecules in the development of inflammatory
processes. Therefore, in this study, we report the cloning and characterization of rabbit CCR2.
Data regarding the activity of the CCR2 antagonist will provide valuable tools to perform
toxicology and efficacy studies in the rabbit model.
Results: Sequence alignment indicated that rabbit CCR2 shares 80 % identity to human CCR2b.
Tissue distribution indicated that rabbit CCR2 is abundantly expressed in spleen and lung.
Recombinant rabbit CCR2 expressed as stable transfectants in U-937 cells binds radiolabeled 125I-
mouse JE (murine MCP-1) with a calculated Kd of 0.1 nM. In competition binding assays, binding of
radiolabeled mouse JE to rabbit CCR2 is differentially competed by human MCP-1, -2, -3 and -4,
but not by RANTES, MIP-1α  or MIP-1β . U-937/rabbit CCR2 stable transfectants undergo
chemotaxis in response to both human MCP-1 and mouse JE with potencies comparable to those
reported for human CCR2b. Finally, TAK-779, a dual CCR2/CCR5 antagonist effectively inhibits
the binding of 125I-mouse JE (IC50 = 2.3 nM) to rabbit CCR2 and effectively blocks CCR2-mediated
chemotaxis.
Conclusion: In this study, we report the cloning of rabbit CCR2 and demonstrate that this
receptor is a functional chemotactic receptor for MCP-1.
Background
Chemokine receptors are seven-transmembrane G-pro-
tein coupled receptors that direct the migration of various
immune cells to the sites of inflammation in addition to
their pivotal role in maintaining immune cell homeosta-
sis in various lymphoid compartments [1,2]. Chemokines
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(8–14 kDa molecular weight), the ligands of chemokine
receptors, are broadly classified based on the positioning
of the two conserved cysteines into the CC, CXC, C or
CX3C family [3]. Binding of chemokines to their cognate
receptors on immune cells triggers a signaling cascade pri-
marily mediated by the Gα i family of G proteins leading to
a variety of cell effector functions including chemotaxis,
degranulation, and release of pro-inflammatory cytokines
such as TNF α  [4].
The CC family chemokine receptor 2 (CCR2) is primarily
expressed in almost all circulating monocytes. CCR2 is
believed to mediate extravasation of blood monocytes to
the sites of inflammation [5-7] and is implicated in the
pathogenesis of several inflammatory diseases such as
rheumatoid arthritis, multiple sclerosis and atherosclero-
sis [8,9]. MCP subfamily members, namely MCP-1, -2, -3,
and -4, bind to CCR2 with high affinity [7,10,11]. Several
studies involving genetic deletion of CCR2 or MCP-1, and
antibody neutralization studies of MCP-1 have clearly
established the critical role of the CCR2/MCP-1 axis in
mediating several key pathogenic events in animal models
of multiple sclerosis and atherosclerosis.
The major challenge in the development of small mole-
cule chemokine receptor antagonists is the lack of cross-
species activity to the receptor in the preclinical species.
For example, BX-471, a small molecule antagonist for
CCR1, exhibits low nano-molar affinity to the human
receptor but has sub-micromolar to high micromolar
affinity to the rat and mouse CCR1 receptors, respectively
[12]. Importantly, BX-471 had intermediate affinity to the
rabbit CCR1 receptor [13]. This imposes significant chal-
lenges to compound testing in efficacy and toxicology
studies in the preclinical models.
In recent years, rabbits have been used to study the patho-
genesis of inflammatory disease model. It has been
recently shown that the therapeutic potential of thiazolid-
inediones in rabbit model of balloon injury and re-
endothelialization is associated with a decrease in MCP-1
expression [14]. In addition, the efficacy of a CXCR2
antagonist has been successfully demonstrated in a
chronic antigen induced arthritis model [15]. Moreover,
CCR1 antagonists have therapeutic benefit in a rabbit
allograft rejection model [13]. In the present study we
report the cloning and functional characterization of the
rabbit CCR2. We also demonstrate that the recently
reported CCR2/CCR5 dual antagonist, TAK-779, exhibits
high level of potency against rabbit CCR2 in both binding
and chemotaxis assays.
Results and Discussion
Cloning and expression analysis of rabbit CCR2
Full-length cDNA sequence of rabbit CCR2 was cloned
from total spleen RNA of New Zealand white rabbits using
a PCR based method. The deduced amino acid sequence
of rabbit CCR2 encoded a protein of 369 amino acids
(Fig. 1) that shared 80 % identity to the human CCR2b
receptor. The sequence alignment with the mouse, rat and
rhesus monkey CCR2 is also depicted in Fig. 2. Rat and
mouse CCR2 contained additional 13 amino acids at the
N-terminus compared to human, monkey and rabbit
CCR2. In addition, one amino acid deletion in rabbit
CCR2 was observed at position 18 (Fig. 2). Cysteines that
were essential for the disulfide bond formation were also
conserved in rabbit CCR2. Based on the SS and 2SS model
[16], cysteine pairs (Cys-72/Cys-119 and Cys-31/Cys-
276) in rabbit CCR2 were highly conserved compared to
its counterparts from all known species. Expression levels
of rabbit CCR2 were also determined in various rabbit tis-
sues using Taqman analysis. Rabbit CCR2 was abundantly
expressed in lungs and spleen compared to low levels of
expression in brain, heart, liver and testis (Fig. 3).
Radioligand binding studies in rabbit CCR2 expressing cells
Stable cell lines expressing rabbit CCR2 in U-937 cells
were generated to characterize the binding properties of
radiolabeled human MCP-1 or mouse JE to rabbit CCR2.
The binding affinity of radiolabeled human MCP-1 or
mouse JE was measured using a competition binding
assay of the respective cold ligands. As shown in Figs. 4,
125I-mouse JE showed high affinity with a calculated Kd of
0.95 ± 0.02 nM and Bmax of 18829 ± 1555 dpm. In con-
trast, 125I-human MCP-1 has less binding affinity to rabbit
CCR2 with lack of saturable binding as high as 6 nM of
hot ligand (data not shown). Detailed examination of the
binding characteristics of radiolabeled human MCP-1 to
rabbit CCR2 will be necessary to resolve this discrepancy.
To address the point, future studies are necessary to under-
stand rabbit CCR2 binding characteristics and pharmacol-
ogy with 125I-rabbit- MCP-1.
Receptor pharmacology of rabbit CCR2 was studied using
a variety of ligands that belonged to the MCP subfamily
and irrelevant ligands such as RANTES, MIP-1α  and MIP-
1β . As expected, human MCP-1, -2, and -4 differentially
competed the binding of radiolabeled mouse JE with Ki
values of 8.4, 13.5 and 0.44 nM, respectively. In contrast,
cold MCP-3 failed to compete JE binding to rabbit CCR2
when used at concentrations as high as 30 nM (Fig. 5A).
In addition, irrelevant ligands that bind with high affinity
to CCR1 or CCR5 were unable to compete binding of radi-
olabeled mouse JE to rabbit CCR2, while cold JE com-
peted binding with a Ki value of 0.116 nM (Fig. 5B). TAK-
779 is a well characterized small molecule antagonist of
both CCR2 and CCR5, and has a 27 nM affinity againstBMC Immunology 2005, 6:15 http://www.biomedcentral.com/1471-2172/6/15
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Full-length rabbit CCR2 cDNA sequence Figure 1
Full-length rabbit CCR2 cDNA sequence. The complete cDNA sequence is shown with nucleotides numbered from the 
putative initiation site (underlined). The deduced amino acid sequence is on the top of nucleotide sequence. Cysteines that 
form the disulfide bonds are labeled in bold for Cys-112, Cys-189 (SS model) and Cys-31, Cys-276 (2SS model), respectively.
   - 9 9 GTTGCTGAGAAGCCTGACACGCCCGTGTCGCCTGGGAGAAGCCATCCACCGAACAGGCAGCTG
                                     M   L   S   T   S   H   S   L   L 9
   - 3 6 GCGGGCATGCACCCGGCTCCCCAGCTCACCCGCAACATGCTGTCCACGTCTCACTCCCTGCTG
+1
 T   R   S   D   L   S   S   P   E   E   A   T   T   V   F   D   Y   D   S   E   P 3 0
    2 7 ACGAGAAGCGACCTCAGCAGCCCCGAGGAAGCCACCACCGTGTTCGACTACGACAGCGAGCCC
C  H  K  T  D  V  K  Q  V  A  A  Q  L  L  P  P  L  Y  S  L  V  5 1
    9 0 TGTCACAAGACCGACGTGAAGCAGGTGGCAGCCCAGCTCCTGCCCCCACTGTACTCGCTCGTG
 F   V   C   G   F   V   G   N   L   L   V   V   L   I  L   I  N   C   K   K   L 7 2
   153  TTCG TCTG CG G CTTCG TGGGCAACCTGCTGGTCGTCCTCATCCTGATCAACTGCAAGAAGCTG
 K   S   M   T   D   I  Y   L   L   N   L   A   I  S   D   L   L   F   L   L   T 9 3
   216  AAGAGCATGACTGACATCTACCTGCTCAACCTGGCCATCTCCGACCTGCTCTTCCTGCTCACC
 L  P  L  W   A  H  Y  A  A  A  E  W   V   F   G   S   A   M C  K   L 1 1 4
   279  CTCCCGCTGTGGGCTCACTACGCCGCCGCCGAGTGGGTCTTCGGAAGTGCTATGTGCAAGCTG
 S   T   G   M   Y  H  M  G   Y   F   G   G   I  F   F   I  I  L   L   T   I 1 3 5
   342  TCCA CGGGGATGTATCACATGGGCTATTTCGGTGGAATCTTCTTCATCATCCTCCTGACCATC
 D   R   Y   L   A   I  V   H   A   V   F   A   L   K   A   R   T   V   T   F   G 1 5 6
   405  G A CAGGTACCTGGCTATCGTCCACGCCGTGTTTGCCTTAAAAGCCAGGACGGTCACCTTTGGG
 V  V  T  S  G  V  T  W   V   A   A   I  F   A   S   V   P   G   I  L   F 1 7 7
   468  G TG G TG A CAAGCGGGGTCACCTGGGTGGCGGCCATATTTGCCTCGGTCCCGGGAATCTTGTTT
 T   R   F   Q   E   E   D   S   R   Y   T C  G   P   D   F   P   L   G   W   K 198
   531  A CCAGGTTCCAAGAAGAAGATTCTCGTTACACCTGTGGCCCCGATTTTCCACTCGGCTGGAAG
 N   F   H   T   I  M   R   N   I  L   S   L   V   L   P   L   L   V   M   V   V 2 1 9
   594  A A TTTCCA CA CCA TCA TGAGGAATATCTTGAGCCTGGTCCTGCCGCTGCTGGTCATGGTCGTG
 C   Y   S   G   I  L   K   T   L   L   R   C   R   N   E   K   R   R   H   R   A 2 4 0
   657  TG CTA CTCGGGGATCCTGAAAACCCTGCTGCGGTGTCGGAACGAGAAGAGGAGGCACAGGGCC
 V   R   L   I  F   A   I  M   V   V   Y   F   L   F   W   A  P  Y  N  V  V 2 6 1
   720  G TG CG G CTCA TCTTCG CCA TCA TG G TG G TTTACTTCCTCTTCTGGGCACCCTACAACGTCGTC
 L   L   L   N   T   F   Q   E   F   F   G   L   N   N C  E   S   S   G   Q   L 2 8 2
   783  CTCCTCCTGAACACCTTCCAGGAGTTCTTCGGCCTGAATAACTGTGAAAGCAGCGGTCAGCTG
 D  R  A  M  Q   V   T   E   T   L   G   M   T   H   C   C   I  N   P   V   V 3 0 3
   846  G A CCGAGCCATGCAGGTGACGGAGACGCTGGGCATGACACACTGCTGCATCAACCCCGTGGTC
 Y   A   F   V   G   E   K   F   R   S   Y   L   S   A   F   F   R   K   H   V   A 3 2 4
   909  TA CG CCTTCG TCGGGGAGAAGTTCCGGAGCTACCTCTCCGCGTTTTTCCGGAAGCACGTCGCC
 K   R   L   C   K   Q   C   P   V   F   Y   R   E   A   A   D   R   V   S   S   T 3 4 5
   972  AAACGCCTCTGCAAACAATGTCCGGTTTTCTACAGGGAGGCAGCAGATCGAGTGAGTTCAACG
 Y   T   H   S   T   G   D   Q   E   I  S   A   G   L   * 3 5 9
  1035  TA CA CCCACTCCACTGGGGACCAGGAAATCTCTGCTGGTCTGTAGGGTGGACAGCCGTCGGCT
  1098  TG CCCTGTTCAAGGAAGGTAGCAATCTGTACATAGTGACAAGCCTCGAGGGCTTGTTGAAGAA
  1161  TA CAGACCTGBMC Immunology 2005, 6:15 http://www.biomedcentral.com/1471-2172/6/15
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CCR2 peptide sequence alignment Figure 2
CCR2 peptide sequence alignment. The CCR2 peptide sequences from mouse, rat, monkey, human and rabbit are aligned 
and the consensus sequence is indicated in the bottom of the alignment. Transmembrane domains (TM) designated based on 
the human CCR2 sequence are also indicated.
 --
   1
  mouse_CCR2 MEDNNMLPQF IHGILSTSHS LFTRSIQELD EGATTPYDYD DGEPCHKTSV 
    rat_CCR2 MEDSNMLPQF IHGILSTSHS LFPRSIQELD EGATTPYDYD DGEPCHKTSV 
 Monkey_CCR2 ~~~~~~~~~~ ~~~MLSTSRS RFIRNTNGSG EEVTTFFDYD YGAPCHKFDV 
     huCCR2b ~~~~~~~~~~ ~~~MLSTSRS RFIRNTNESG EEVTTFFDYD YGAPCHKFDV 
 rabbit_CCR2 ~~~~~~~~~~ ~~~MLSTSHS LLTRSDLSSP EEATTVFDYD .SEPCHKTDV 36 
   Consensus MED-NMLPQF IHGMLSTSHS LF-RS--ES- EEATT-FDYD -GEPCHKTDV 
   TM1     TM2 
    -------------------------     ------------ 
  mouse_CCR2 KQIGAWILPP LYSLVFIFGF VGNMLVIIIL IGCKKLKSMT DIYLLNLAIS 
    rat_CCR2 KQIGAWILPP LYSLVFIFGF VGNMLVIIIL ISCKKLKSMT DIYLFNLAIS 
 Monkey_CCR2 KQIGAQLLPP LYSLVFIFGF VGNMLVVLIL INCKKLKSLT DIYLLNLAIS 
     huCCR2b KQIGAQLLPP LYSLVFIFGF VGNMLVVLIL INCKKLKCLT DIYLLNLAIS 
 rabbit_CCR2 KQVAAQLLPP LYSLVFVCGF VGNLLVVLIL INCKKLKSMT DIYLLNLAIS 86 
   Consensus KQIGAQLLPP LYSLVFIFGF VGNMLVVLIL INCKKLKSMT DIYLLNLAIS 
TM3
             ----------         -------------------------- 
  mouse_CCR2 DLLFLLTLPF WAHYAANEWV FGNIMCKVFT GLYHIGYFGG IFFIILLTID 
    rat_CCR2 DLLFLLTLPF WAHYAANEWV FGNIMCKLFT GLYHIGYFGG IFFIILLTID 
 Monkey_CCR2 DLLFLITLPL WAHSAANEWV FGNAMCKLFT GLYHIGYLGG IFFIILLTID 
     huCCR2b DLLFLITLPL WAHSAANEWV FGNAMCKLFT GLYHIGYFGG IFFIILLTID 
 rabbit_CCR2 DLLFLLTLPL WAHYAAAEWV FGSAMCKLST GMYHMGYFGG IFFIILLTID 136 
   Consensus DLLFLLTLPL WAHYAANEWV FGNAMCKLFT GLYHIGYFGG IFFIILLTID 
              TM4 
--------------------------
  mouse_CCR2 RYLAIVHAVF ALKARTVTFG VITSVVTWVV AVFASLPGII FTKSKQDDHH 
    rat_CCR2 RYLAIVHAVF ALKARTVTFG VITSVVTWVV AVFASLPGII FTKSEQEDDQ 
 Monkey_CCR2 RYLAIVHAVF ALKARTVTFG VVTSVITWLV AVFASVPGII FTKCQEEDSV 
     huCCR2b RYLAIVHAVF ALKARTVTFG VVTSVITWLV AVFASVPGII FTKCQKEDSV 
 rabbit_CCR2 RYLAIVHAVF ALKARTVTFG VVTSGVTWVA AIFASVPGIL FTRFQEEDSR 186 
   Consensus RYLAIVHAVF ALKARTVTFG VVTSVVTWVV AVFASVPGII FTK-Q-EDSV 
    TM5 
       --------------------------- 
  mouse_CCR2 YTCGPYFTQL WKNFQTIMRN ILSLILPLLV MVICYSGILH TLFRCRNEKK 
    rat_CCR2 HTCGPYFPTI WKNFQTIMRN ILSLILPLLV MVICYSGILH TLFRCRNEKK 
 Monkey_CCR2 YICGPYFPRG WNNFHTIMRN ILGLVLPLLI MVICYSGILK TLLRCRNEKK 
     huCCR2b YVCGPYFPRG WNNFHTIMRN ILGLVLPLLI MVICYSGILK TLLRCRNEKK 
 rabbit_CCR2 YTCGPDFPLG WKNFHTIMRN ILSLVLPLLV MVVCYSGILK TLLRCRNEKR 236 
   Consensus YTCGPYFPRG WKNFHTIMRN ILSLVLPLLV MVICYSGILK TLLRCRNEKK 
       TM6 
     ----------------------              ---- 
  mouse_CCR2 RHRAVRLIFA IMIVYFLFWT PYNIVLFLTT FQESLGMSNC VIDKHLDQAM 
    rat_CCR2 RHRAVRLIFA IMIVYFLFWT PYNIVLFLTT FQEFLGMSNC VVDMHLDQAM 
 Monkey_CCR2 RHRAVRLIFT IMIVYFLFWT PYNIVILLNT FQEFFGLSNC ESTRQLDQAT 
     huCCR2b RHRAVRVIFT IMIVYFLFWT PYNIVILLNT FQEFFGLSNC ESTSQLDQAT 
 rabbit_CCR2 RHRAVRLIFA IMVVYFLFWA PYNVVLLLNT FQEFFGLNNC ESSGQLDRAM 286 
   Consensus RHRAVRLIFA IMIVYFLFWT PYNIVLLLNT FQEFFGLSNC ES--QLDQAM 
   TM7 
     -------------------- 
  mouse_CCR2 QVTETLGMTH CCINPVIYAF VGEKFRRYLS IFFRKHIAKR LCKQCPVFYR 
    rat_CCR2 QVTETLGMTH CCVNPIIYAF VGEKFRRYLS IFFRKHIAKN LCKQCPVFYR 
 Monkey_CCR2 QVTETLGMTH CCINPIIYAF VGEKFRRYLS MFFRKYITKR FCKQCPVFYR 
     huCCR2b QVTETLGMTH CCINPIIYAF VGEKFRRYLS VFFRKHITKR FCKQCPVFYR 
 rabbit_CCR2 QVTETLGMTH CCINPVVYAF VGEKFRSYLS AFFRKHVAKR LCKQCPVFYR 336 
   Consensus QVTETLGMTH CCINPIIYAF VGEKFRRYLS IFFRKHIAKR LCKQCPVFYR 
  mouse_CCR2 ETADRVSSTF TPSTGEQEVS VGL 
    rat_CCR2 ETADRVSSTF TPSTGEQEVS VGL 
 Monkey_CCR2 ETVDGVTSTN TPSTAEQEVS VGL 
     huCCR2b ETVDGVTSTN TPSTGEQEVS AGL 
 rabbit_CCR2 EAADRVSSTY THSTGDQEIS AGL 359 
   Consensus ETADRVSST- TPSTGEQEVS VGL BMC Immunology 2005, 6:15 http://www.biomedcentral.com/1471-2172/6/15
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human CCR2b receptor [17]. We tested the activity of
TAK-779 on rabbit CCR2 transfected cells using radiola-
beled mouse JE in a standard competition binding assay.
As shown in Fig. 5C, TAK-779 was also highly potent
against rabbit CCR2 with an IC50 of 2.3 nM.
Functional characterization of Rabbit CCR2 stable cell line
In order to confirm whether rabbit CCR2 expressed in U-
937 cells is functionally coupled to Gα i family of G pro-
teins, chemotaxis assays were conducted using both
parental U-937 and U-937/rabbit CCR2 stable transfect-
ants. Cells were incubated in the top chamber in the pres-
ence of increasing concentrations of ligand in the lower
chamber. Parental U-937 failed to migrate to either
human MCP-1 or mouse JE. In contrast, U-937/rabbit
CCR2 stable transfectants migrated effectively to either
human MCP-1 or mouse JE (Fig. 6A and 6B). The maxi-
mal migration was observed at roughly 4 nM of ligand
and ranged from 20–40 % total input compared to 0.5–1
% of cells migrating in the absence of any ligand. A typical
bell-shaped curve was observed in the chemotaxis
response with either human MCP-1 or mouse JE. As
expected, both parental and rabbit CCR2 stable cell lines
migrated well to the CXCR4 ligand SDF-1α  (Fig. 6C). The
antagonist effect of TAK-779 was also examined against
rabbit CCR2 in the presence of defined concentration of
either mouse JE or hMCP-1 (4 nM). Preincubation of rab-
bit CCR2 expressing cells with TAK-779 effectively
blocked migration of either mouse JE or hMCP-1 with an
Tissue distribution of rabbit CCR2 Figure 3
Tissue distribution of rabbit CCR2. The mRNA levels from rabbit tissues were quantitated by Taqman technique as 
described under "Materials and Methods". CCR2 mRNA levels are expressed as the ratio of CCR2 and GAPDH. Error bars 
represent the mean ± standard deviation of quadruplicate values.
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IC50 of 98 nM and 4 nM, respectively (Fig. 6D and 6E). As
expected, TAK-779 inhibited MCP-1 dependent migration
of U-937/hCCR2b stable cells with an IC50 of 3.8 nM (Fig.
6F)
Conclusion
In summary, we have cloned the full-length rabbit CCR2
cDNA and proved that the receptor is functional by
expressing rabbit CCR2 in U-937 cells. The sequence of
rabbit CCR2 will provide additional insight into the
molecular evolution of chemokine receptors in different
species. More importantly, the data obtained on cross-
species activity of the CCR2 antagonist will provide valu-
able tools to perform toxicology and efficacy studies in the
rabbit model.
Methods
Materials
Recombinant human chemokines (MCP-1, -2, -3, -4,
RANTES, MIP-1α , MIP-1β ) were purchased from Pepro
Tech (Rocky Hill, NJ). Mouse JE and human SDF-1α  were
obtained from R&D Systems (Minneapolis, MN). Radi-
olabeled ligands (125I-human MCP-1 and 125I-mouse JE)
were purchased from Perkin Elmer (Boston, MA). RPMI
Saturation binding of mouse JE to rabbit CCR2 Figure 4
Saturation binding of mouse JE to rabbit CCR2. Various concentrations of 125I-mouse JE was added to U-937/rabbit 
CCR2 stable transfectants as described under "Materials and Methods". The nonspecific binding was determined by including 
100-fold excess of unlabeled chemokine. Specific binding was calculated by subtracting nonspecific binding from total binding. 
The dissociation constant (Kd) was calculated using the nonlinear curve fit. Each point represents mean values of the duplicates 
from one of two representative assays. The scatchard plot is depicted in the insert.
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Competition assays of various chemokines on U-937/rabbit CCR2 stable transfectants Figure 5
Competition assays of various chemokines on U-937/rabbit CCR2 stable transfectants. (A) U-937/rabbit CCR2 
stable cells (104 cells/well) were incubated with 125I-mouse JE (0.11 nM) for 2 hours in the presence of unlabeled chemokines 
(Human MCP-1, -2, -3, -4) at concentrations as high as 30 nM. (B). U-937/rabbit CCR2 stable cells (104 cells/well) were incu-
bated with 125I-mouse JE (0.11 nM) for 2 hours in the presence of unlabeled chemokines (mouse JE, hMIP-1α , hMIP-1β  and 
hRANTES) at concentrations as high as 30 nM. (C) Competition binding assay was performed on U-937/rabbit CCR2 stable 
cells (104 cells/well) that were incubated with 125I-mouse JE (0.11 nM) for 2 hours in the presence of various concentrations of 
TAK-779. Each point represents mean values ± standard deviations of the duplicates from one of two representative assays.
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Chemotaxis assay in U-937/rabbit CCR2 stable transfectants Figure 6
Chemotaxis assay in U-937/rabbit CCR2 stable transfectants. Chemotaxis assays were performed in parental U-937 
or U-937/rabbit CCR2 stable transfectants using increasing concentrations of human MCP-1 (A), mouse JE (B) or human SDF-
1α  (C). The effect of TAK-779 on rabbit CCR2-induced chemotaxis was tested in the presence of 4 nM of mouse JE (D) or 
hMCP-1 (E). Effect of TAK-779 on hCCR2-induced chemotaxis in the presence of 4 nM of hMCP-1 (F). Each point represents 
means of the triplicate from one assay.
0.001 0.01 0.1 1 10 100 1000
0
10
20
30
40
50
60
70
Rabbit CCR2 Cells
Parental U-937 Cells
A
hMCP-1 [nM]
%
 
 
C
e
l
l
 
M
i
g
r
a
t
i
o
n
0.001 0.01 0.1 1 10 100 1000
0
10
20
30
40
50
60
70
Rabbit CCR2 Cells
Parental U-937 Cells
B
JE [nM]
%
 
C
e
l
l
 
M
i
g
r
a
t
i
o
n
0.001 0.01 0.1 1 10 100 1000
0
10
20
30
40
50
60
70 Rabbit CCR2 Cells
Parental U-937 Cells
C
SDF-1D [nM]
%
 
 
C
e
l
l
 
M
i
g
r
a
t
i
o
n
0
0
20
40
60
80
100
120
-9 -8 -7 -6 -5 -4
D
TAK-779, Log[M]
%
 
M
a
x
i
m
a
l
 
M
i
g
r
a
t
i
o
n
0
0
25
50
75
100
-11 -10 -9 -8 -7 -6 -5
F
TAK-779, log[M]
%
 
M
a
x
i
m
a
l
 
M
i
g
r
a
t
i
o
n
0
0
20
40
60
80
100
-11 -10 -9 -8 -7 -6 -5
E
TAK-779, log[M]
%
 
M
a
x
i
m
a
l
 
M
i
g
r
a
t
i
o
nBMC Immunology 2005, 6:15 http://www.biomedcentral.com/1471-2172/6/15
Page 9 of 10
(page number not for citation purposes)
1640, bovine albumin serum (BSA) and 4-(2-hydroxye-
thyl)-1-piperazineethanesulfonic acid (HEPES) were pur-
chased from Sigma (Gaithersburgh, MD). Polymeric
chain reaction (PCR) and Taqman primers were pur-
chased from Qiagen (Valencia, CA). The CCR5/CCR2
dual antagonist TAK-779 was synthesized as described
elsewhere [14].
Rabbit cDNA cloning
Total RNA was prepared from the spleen of New Zealand
white rabbits by the Trizol method and the cDNA was
transcribed by using SuperScript™ First-Strand Synthesis
System for RT-PCR (Invitrogen, Carlson, CA). Then the
cDNA was amplified by PCR by using conserved primers
(primer 1: 5'-GTATTCATCTTTGGTTTTGTGGGCAACATG-
3' and primer 2: 5'-CAAAGGTAACTGTCCTGGCTTT-
TAAAGCAA-3'). The resultant PCR fragment was
sequenced and this information was used to design the
rabbit CCR2 gene specific primers. Rabbit CCR2 gene spe-
cific primers were used to amplify two fragments of rabbit
cDNA by 5'- and 3'- rapid amplification of cDNA ends
(RACE) using SMART RACE cDNA Amplification Kit
(Clonetech, Palo Alto, CA). The sequence information
from 5'- and 3'- RACE products was further used to design
two primers (5'-GGTTGCTGAGAAGCCTGACACGC-3',
and 5'-CAGGTCTGTATTCTTCAACAAGCCCTCG-3') out
of start and stop codons, and full-length rabbit CCR2
cDNA was cloned using PCR amplification. The final PCR
product with corresponding size was cloned to PCRII-
TAPO (Invitrogen) and sequenced.
Tissue distribution
Rabbit cDNA from brain, heart, liver, lung, spleen and tes-
tis were quantitated for expression levels of CCR2 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by
Taqman method. TaqMan primers and probes were
designed using the Primer Express Computer Program
(Applied Biosystems, Foster City, CA). The forward and
reverse primers and probe selected for rabbit CCR2 are: 5'-
catgacacactgctgcatcaac-3', 5'-gagaggtagctccggaacttctc-3'
and 5'-[6-FAM]-ccgtggtctacgccttcgtcgg-[TAMRA-6-FAM]-
3'. The forward, reverse primers and probe selected for
rabbit GAPDH are: 5'-ggatttggccgcattgg-3', 5'-caacatc-
cactttgccagagttaa-3' and 5'-[6-FAM]-cgcctggtcaccagggctgct-
[TAMRA-6-FAM]-3'. Amplification mixture contained a
total volume of 10 µl with 6 µl of TaqMan universal PCR
master mixture (300 nM forward primer, 300 nM reverse
primer, and 900 nM probe) and 4 µl of diluted samples.
Taqman amplification was conducted on a ABI PRISM
7900HT Sequence Detector System (Applied Biosystems,
Foster City, CA) with the following thermal profile: 1 cycle
each of 50°C for 2 minutes and 95°C for 10 minutes fol-
lowed by 40 cycles each of 95°C for 15 seconds and 60°C
for 1 minute. Data was analyzed using a built-in standard
curve method.
Generation of retrovirus infected rabbit CCR2 stable cell 
line
Rabbit cDNA described above was amplified by PCR with
primer 11: 5'-ggaggcagatctcgaacaggcagctggcgg-3' and
primer 12: 5'-ttattggaattccaagccgacggctgtcca-3' (under-
lined nucleotides are the cleavage sites of Bgl II and EcoR
I, respectively). The resulted PCR fragment was digested
with Bgl II and EcoR I, and then subcloned into the corre-
sponding site of pMSCVpuro retroviral expression vector
(BD Biosciences, CA). Lipofectamine-mediated transfec-
tion was carried out in the AmphoPack 293 packaging cell
line (BD Biosciences, CA) with a full-length cDNA for rab-
bit CCR2 in the retroviral expression vector pMSCVpuro,
containing a puromycin resistance selection marker.
Thirty six hours after transfection, the pool of viral
supernatant was recovered from the packaging cells, cen-
trifuged, and polybreen was added to a final concentra-
tion of 8 µg/ml. The viral supernatant was then added to
parental U-937 cells in a tissue culture treated flask and
the infection was allowed to proceed for 7 hours. At this
time, additional medium was added to the packaging cells
to generate more virus. After 7 hours, the second pool of
viral supernatant was prepared as the first, except with 4
µg/ml polybreen. U-937 cells were resuspended in this
viral supernatant and the infection was allowed to pro-
ceed overnight. Then the U-937 cells were placed into
fresh medium without any selection. After 18 hours, the
medium was changed to selection medium containing 0.4
µg/ml puromycin. The pool of stably transfected clones
was propagated for binding and chemotaxis assays.
Equilibrium binding assays
Equilibrium binding assay was conducted in RPMI 1640
medium with 10 mM HEPES and 0.2% BSA in room
temperature with constant shaking for 2 hours. Reaction
mixture contained a total volume of 100 µl with various
concentrations of 125I-labeled ligands (125I-human MCP-1
or 125I-mouse JE), U-937/rabbit CCR2 stable transfectants
(105 cells /well for 125I-human MCP-1 and 104 cells /well
for  125I-mouse JE) in the presence or absence of corre-
sponding cold ligand. Nonspecific binding was deter-
mined by 100-fold excess of cold ligand. Reactions were
stopped by separation using the glass fiber filter (Wallac
Printed Filtermat A) on a Tomtec Harvester 96-2 (Ham-
den, CT). Filters were subsequently washed 5 times with
wash buffer (10 mM HEPES, 500 mM NaCl, pH 7.4) to
remove the unbound radioligand. Finally, bound radioli-
gand was quantitated using a liquid scintillation counter
(Wallac 1205 Betaplate, Perkin Elmer). Dissociation con-
stant (Kd) and maximum binding (Bmax) were calculated
by non-linear regression with Graphpad Prism 4.01 (San
Diego, CA).BMC Immunology 2005, 6:15 http://www.biomedcentral.com/1471-2172/6/15
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Competition binding assays
The assay was conducted under the identical conditions as
saturation binding assay described above with the radiola-
beled ligand concentration fixed (0.11 nM 125I-mouse JE)
in the presence of various concentrations of unlabeled
chemokines or TAK-779. Values of IC50 were calculated by
fitting the competition curves with Graphpad Prism 4.01.
Chemotaxis assays
Chemotaxis assay was performed as described elsewhere
[18] with a few modifications. Parental U-937 or U-937/
rabbit CCR2 stable transfectants were harvested, counted
and resuspended at a final cell density of 5 × 106 /ml in
chemotaxis buffer (RPMI 1640 medium, containing 0.3%
BSA and 1 mM HEPES). Chemokines were diluted to
1000 ng/ml stock and serially diluted (1:3) in migration
buffer in a Costar 96 well plate (Cat #3790, Costar,
Corning NY). Thirty microliters of each chemokine dilu-
tion were transferred to the corresponding well in the bot-
tom chamber of a ChemoTX 96 well migration plate (5
µM pore size; Neuroprobe, Gaithersburg, MD). The
ChemoTX filter unit was assembled and 50 µl of cells were
added to the top chamber and incubated for 2.5 hours.
Plates were then removed and cells were aspirated off the
filter top. The cells that had migrated to the bottom
chamber were pulsed with 5 µl of Aqueous One Solution
(Promega, Madison, WI) and incubated for an additional
30–60 minutes at 37°C. Plates were shaken gently to per-
mit uniform mixing and read at 490 nm in a Spectramax
Plus reader (Molecular Dynamics, Piscataway, NJ). Cell
standard curves were incorporated into the bottom of
each plate with cell number ranges from 0–150,000 cells/
well. The results were expressed as percent cell migration
versus chemokine concentration. For compound testing,
TAK-779 was diluted in DMSO at various concentrations
and added to both the top and bottom chambers and
chemotaxis assay was performed in the presence of 4 nM
of mouse JE as described above.
Abbreviations
CCR2, CC chemokine receptor 2; MCP, monocyte chem-
oattactant protein; RANTES, regulated on activation-regu-
lated chemokine; MIP, macrophage inflammatory
protein; GAPDH, glyceraldehyde-3-phosphate dehydro-
genase; RACE, rapid amplification of cDNA ends, HEPES,
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; BSA,
bovine serum albumin; PCR, polymerase chain reaction.
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